Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).
Comparison 7: Structured GP follow‐up showed no clear difference in repetition of SH at post‐intervention (hospital records) compared with TAU or another comparator (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Low dose calcineurin inhibitors (CNI) showed no clear difference in graft loss compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: hypertension compared with to standard dose CNI (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: CMV infection compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: malignancy compared with to standard dose CNI (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in death compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in acute rejection compared with to standard dose CNI (moderate certainty).
It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes global state: no improvement ‐ short term compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) may leads to higher behaviour: deterioration of behaviour (categorised as reason to… compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (low certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: unspecified extrapyramidal symptoms compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in adverse event: death compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in global state: needing additional medication (sedation with chloral… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (low certainty).